Prema Maria Mertz

Array ( [id] => 17140211 [patent_doc_number] => 20210308222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES [patent_app_type] => utility [patent_app_number] => 17/353987 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23541 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 252 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17353987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20321401 [patent_doc_number] => 20250333489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-30 [patent_title] => EPO VARIANTS AND MODULATORS [patent_app_type] => utility [patent_app_number] => 18/569499 [patent_app_country] => US [patent_app_date] => 2021-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5702 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18569499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18793933 [patent_doc_number] => 11827685 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-28 [patent_title] => Masked cytokine polypeptides [patent_app_type] => utility [patent_app_number] => 17/339801 [patent_app_country] => US [patent_app_date] => 2021-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 132 [patent_no_of_words] => 157118 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17339801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18162366 [patent_doc_number] => 20230028959 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => MASKED CYTOKINE POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/339810 [patent_app_country] => US [patent_app_date] => 2021-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 157104 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17339810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17095459 [patent_doc_number] => 20210283250 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => METHOD FOR TREATING RHEUMATOID ARTHRITIS WITH A HUMAN IL-6 RECEPTOR ANTIBODY AND METHOTREXATE [patent_app_type] => utility [patent_app_number] => 17/334341 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17334341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18685194 [patent_doc_number] => 11780912 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => Composition for prophylaxis or treatment of IL-8 related diseases [patent_app_type] => utility [patent_app_number] => 17/333256 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 48 [patent_no_of_words] => 57836 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17333256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855570 [patent_doc_number] => 12258393 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha [patent_app_type] => utility [patent_app_number] => 17/325743 [patent_app_country] => US [patent_app_date] => 2021-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 22 [patent_no_of_words] => 25866 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 344 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17325743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18931096 [patent_doc_number] => 11883490 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Induction of IL-12 using immunotherapy [patent_app_type] => utility [patent_app_number] => 17/326009 [patent_app_country] => US [patent_app_date] => 2021-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5349 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17326009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19165829 [patent_doc_number] => 11981716 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-14 [patent_title] => Activatable interleukin-2 polypeptides and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/320779 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 98 [patent_no_of_words] => 33942 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214542 [patent_doc_number] => 20210347879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => ANTI-GM-CSF ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/314198 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18087 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18233204 [patent_doc_number] => 11597753 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Activatable IL2 composition and methods of use [patent_app_type] => utility [patent_app_number] => 17/245679 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 25 [patent_no_of_words] => 8426 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666296 [patent_doc_number] => 11773174 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Anti-IL1RAP antibodies and their use for treating humans [patent_app_type] => utility [patent_app_number] => 17/241609 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 23 [patent_no_of_words] => 14069 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17022340 [patent_doc_number] => 20210246211 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => DRUG DELIVERY COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/241935 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -133 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18575503 [patent_doc_number] => 11732017 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use [patent_app_type] => utility [patent_app_number] => 17/240260 [patent_app_country] => US [patent_app_date] => 2021-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25136 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356831 [patent_doc_number] => 20220017627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/232979 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48736 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17232979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18932310 [patent_doc_number] => 11884717 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein [patent_app_type] => utility [patent_app_number] => 17/226506 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 53 [patent_no_of_words] => 37288 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17226506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18604687 [patent_doc_number] => 11746137 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Immunostimulating IL-2 analogs [patent_app_type] => utility [patent_app_number] => 17/915808 [patent_app_country] => US [patent_app_date] => 2021-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 25015 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17915808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17434807 [patent_doc_number] => 11260113 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-03-01 [patent_title] => NK-lysin peptide compositions and methods for their use as antimicrobial/antiviral agents [patent_app_type] => utility [patent_app_number] => 17/213483 [patent_app_country] => US [patent_app_date] => 2021-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 32 [patent_no_of_words] => 12307 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17213483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20824944 [patent_doc_number] => 12678486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-14 [patent_title] => Cell immunotherapy for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 17/904408 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 16888 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16962964 [patent_doc_number] => 20210214463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => Bi-Specific Fusion Proteins [patent_app_type] => utility [patent_app_number] => 17/212270 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35330 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212270 [rel_patent_id] =>[rel_patent_doc_number] =>)